HRMY
Harmony Biosciences Holdings
NASDAQ: HRMY · HEALTHCARE · BIOTECHNOLOGY
$30.18
-2.31% today
Updated 2026-06-05
Market cap
$1.83B
P/E ratio
12.74
P/S ratio
2.03x
EPS (TTM)
$2.48
Dividend yield
—
52W range
$26 – $41
Volume
0.8M
Harmony Biosciences Holdings (HRMY) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$30.18
12-Month target
$22.07
2030 Target
—
Intrinsic (DCF)
—
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0.3B | $0.4B | $0.6B | $0.7B | $0.9B |
| EPS | — | — | — | — | — |
CAGR applied: — (capped 20%) · P/E: 12.74x (capped 25x) · Margin: 16.20%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.